Artificial Heart Trial Continues After Patient Death: French Heartmaker

French biomedical firm Carmat confirmed it would implant its experimental artificial heart into another three people, as planned, after the first recipient died.

French biomedical firm Carmat confirmed on Tuesday it would implant its experimental artificial heart into another three people, as planned, after the first recipient of the artificial heart died.

In an email to AFP, the company said it was too soon to draw conclusions about the device's efficacy.

Tips to Prevent Heart Attacks
Heart Attack occurs when the flow of oxygenated blood to heart muscles is hindered or stopped due to built-up of plaques in coronary arteries. Heart Attack is the No.1 killer among Indians.

A 76-year-old recipient died over the weekend, 75 days after receiving the gadget, whose trials are being closely followed by French investors.

"It is premature to draw conclusions based on the outcomes from a single patient," said the the firm, whose stock was suspended at its own request on Tuesday.

"Carmat does not intend announcing the results of this trial until the implants and 30-day followup of all four intended four patients are complete."

Congestive Heart Failure (Congestive Cardiac Failure) Current Management
Congestive heart failure (CHF) is a condition in which the heart fails to work adequately as a pump that can deliver oxygen rich blood to the body.

The septuagenarian with terminal heart disease was one of four people, all with end-stage heart failure, selected for the experiment.

The trial would be considered a success if each of the four survive for at least a month.

Diet, Lifestyle and Heart Disease
The correlation between diet, lifestyle and heart disease. The importance of balanced diet life style and exercise for controlling heart disease.

Artificial hearts have been in use for many years as a temporary fix for patients with chronic heart problems.

Unlike these mostly synthetic pumps, the Carmat product aims to provide a longer-term solution -- up to five years -- to bridge the wait for a donor heart and enabling hospitalised patients to go back home and even resume work.

The device, a self-contained unit implanted in a patient's chest, is a mix of synthetic materials and animal tissue, and seeks to mimic the form and function of an actual human heart.

Nearly 100,000 people in Europe and the United States are in need of a heart transplant, according to Carmat.

Source-AFP